Antiplatelet Resumption in Conservatively Managed Chronic Subdural Hematoma
In patients with chronic subdural hematoma managed conservatively without burr-hole drainage, resume antiplatelet therapy after 2 weeks of withholding, as this timeframe balances hemorrhagic and thromboembolic risks without increasing reaccumulation rates.
Evidence-Based Timing
The 2026 British Journal of Neurosurgery guidelines do not provide specific recommendations for antiplatelet resumption timing in non-operative cSDH management 1. However, research evidence fills this critical gap:
Two-Week Threshold
- A 2021 retrospective analysis of 221 conservatively managed cSDH patients found that 2 weeks was the most commonly advised withholding period (36.36% of cases) 2
- Critically, there was no significant difference in reaccumulation rates between patients who withheld antiplatelets for 2 weeks versus those who stopped for longer than 2 weeks (P = 0.57) 2
- The overall re-referral rate was only 5.88%, suggesting conservative management with temporary antiplatelet cessation is generally safe 2
Clinical Reasoning
The rationale for 2-week resumption includes:
- Hemorrhagic stabilization: Most cSDH membranes stabilize within 2 weeks when the antiplatelet effect is removed
- Thromboembolic risk mitigation: Prolonged withholding beyond 2 weeks increases cardiovascular and cerebrovascular event risk without additional hemorrhagic benefit 2
- Practical monitoring: Two weeks allows for clinical reassessment with repeat imaging if symptoms change
Monitoring Strategy During Withholding Period
While awaiting the 2-week mark:
- Perform neurological observations at appropriate frequency to detect clinical deterioration 1
- Consider repeat CT imaging at 1-2 weeks to assess hematoma evolution
- If hematoma enlarges or symptoms worsen, surgical intervention becomes indicated and antiplatelet resumption should be delayed until after surgery 1
Special Considerations
High Thromboembolic Risk Patients
For patients with:
- Atrial fibrillation (most common indication, 29.6%) 3
- Prosthetic heart valves (16.6%) 3
- Recent myocardial infarction (14.1%) 3
- Prior stroke/TIA (11.6%) 3
Consider earlier resumption (even <2 weeks) if imaging shows hematoma stability or regression, as one case report demonstrated complete cSDH resolution with aspirin suspension alone 4. The thromboembolic risk (6.8% without resumption vs 2.9% with resumption, P<0.001) may outweigh hemorrhagic concerns in stable hematomas 3.
Documentation Requirements
When withholding beyond 2 weeks is deemed necessary:
- Document clear clinical reasoning for extended withholding 2
- Specify exact resumption date
- Arrange definitive follow-up appointment
- Communicate plan to patient's cardiologist or primary care provider
Common Pitfalls to Avoid
Indefinite withholding: Never leave antiplatelet cessation open-ended—this dramatically increases thromboembolic events without proven hemorrhagic benefit 2, 3
Ignoring indication severity: A patient with recent coronary stent requires more aggressive resumption planning than one on aspirin for primary prevention
Lack of imaging confirmation: Resume only after confirming hematoma stability or regression on repeat CT, particularly if symptoms persist
Failure to bridge high-risk patients: Consider cardiology consultation for patients with mechanical valves or recent acute coronary syndrome who may need alternative strategies